Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

(NASDAQ: QNTM) (CSE: QNTM) Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling immediate advancement into Phase 2 clinical development. The IND submitted was approximately 15,000 pages long, and the Company reported cash, digital assets and liquid investments totaling over USD $10 million as of March 31, 2026. The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market is projected to expand from USD $1.16 billion in 2025 to USD $1.31 billion by 2026, reflecting a CAGR of 13.7%. The overall global MS therapeutics market is anticipated to reach approximately USD $38.62 billion by 2030, growing at a CAGR of 5.93%. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd and is entitled to royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company projects the initiation of patient enrollment and drug administration for the Phase 2 clinical trial as quickly as possible and anticipates that Lucid-MS could become a disease-modifying therapy for MS.

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

(NASDAQ: QNTM) (CSE: QNTM) — Quantum BioPharma Ltd. is developing Lucid-MS, a patented, first-in-class drug candidate targeting the myelin sheath to prevent, stop, and potentially reverse its degradation in multiple sclerosis. The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is forecast to reach $38.62 billion by 2030. Quantum retains ownership of 19.84% (as of March 31, 2026) of unbuzzd at www.unbuzzd.com. The agreement with unbuzzd includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Lucid-MS has been shown to prevent and reverse myelin degradation in preclinical models. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. The company is dedicated to building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders.

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

(NASDAQ: QNTM) (CSE: QNTM) Quantum BioPharma Ltd. today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio @ IBN. Quantum BioPharma Ltd. is developing Lucid-MS, a patented, first-in-class drug candidate that is now preparing to move into phase 2 clinical trials. More than 2.9 million people across the globe are currently living with multiple sclerosis (“MS”). Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), retaining ownership of 19.84% (as of March 31, 2026) of Unbuzzd. The agreement with Unbuzzd includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company is dedicated to building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders.

The Quest to Repair What Multiple Sclerosis Takes Away

(NASDAQ: QNTM) (CSE: QNTM) Quantum BioPharma Ltd. is developing Lucid-MS, a patented, first-in-class drug candidate that directly targets the myelin sheath destroyed by multiple sclerosis (“MS”). The company is preparing to move Lucid-MS into phase 2 clinical trials. More than 2.9 million people across the globe are currently living with MS. Quantum BioPharma is part of a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, alongside Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY). Existing therapies can slow the advance of MS, but none can halt it outright. The company is determined working to change that outcome. The potential treatment is now preparing to move into phase 2 clinical trials.

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

(NASDAQ: QNTM) (CSE: QNTM) Quantum BioPharma Ltd. today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio @ IBN. Quantum BioPharma Ltd. is advancing Lucid-MS, a patented, first-in-class drug candidate that is preparing to enter phase 2 clinical trials. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 19.84% (as of March 31, 2026) of Unbuzzd. The agreement with Unbuzzd includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. The company is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

(NASDAQ: QNTM) (CSE: QNTM) Quantum BioPharma Ltd. is advancing Lucid-MS, a patented, first-in-class drug candidate that directly targets the myelin sheath destroyed by multiple sclerosis (“MS”). More than 2.9 million people worldwide are living with MS today, and current therapies can slow progression but cannot halt it. Lucid-MS is preparing to enter phase 2 clinical trials. Quantum BioPharma is focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases. Other companies mentioned in this space include Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN). The company is challenging the reality that every approved treatment falls short of stopping the disease cold. The company projects that Lucid-MS will take a fundamentally different approach by directly targeting the myelin sheath.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

(NASDAQ: QNTM) (CSE: QNTM) Quantum BioPharma Ltd. has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC beginning on June 8, 2026, for a fee of US$250,000. The agreement covers a period of 6 months and includes services such as creating company profiles, media distribution, building a digital community, marketing of news distribution, and lead generation campaigns. The Agency is arm’s-length to the Company and neither the Agency nor its principals hold an equity interest in the Company’s securities. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. The company’s lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company projects future development and commercialization of its products and technologies, as well as increased awareness among investors and other market participants.